At a health informatics congress in Brazil, a ministry and a technology company signed an agreement that will put artificial intelligence inside the country's public health system. The Unified Health System covers more than 210 million people across federal, state and municipal tiers. The software will handle voice and text triage, rank waiting lists, support clinicians and steer preventive care. Technical roadmapping begins in early 2027. For now there is a signature and a stated intention, which is worth remembering before anyone reads the results into it.

The link to Britain is indirect but real. The supplier, Sword, already works with public systems in Portugal, Greece and the UK, so English leaders are watching a company they know being trusted with something far larger. The function being handed over matters more than the vendor. Deciding who is seen first is among the most politically charged acts a health system performs. In England it sits beneath a waiting list that has stayed close to seven million pathways for long stretches, and beneath a government commitment to have 92 per cent of patients treated within 18 weeks by March 2029.

Brazil shows where the NHS 10 Year Health Plan leads if taken literally. That plan promises a move from analogue to digital and treats the NHS App as the front door to care. Automated triage and prioritisation are the obvious next step for a system short of capacity, and the financial case writes itself. What remains unsettled is who answers for a ranking produced by software. A clinician who reorders a list can explain the decision to a patient, a coroner or an ombudsman. A model trained on historical referral patterns can reproduce the inequities embedded in them, such as longer waits in deprived areas, and do so at scale before anyone notices.

Brazil's health ministry has said the technology must narrow access gaps. That is a sound test and a demanding one, because equity claims require measurement by deprivation, ethnicity, disability and digital access. The NHS holds better data for this than most systems, yet it is scattered across trusts, integrated care boards and devolved administrations running different platforms. Brazil faces a comparable federal patchwork, and its decision to span all three tiers of government concedes that a single-region pilot would prove little. England has a long record of local pilots that impress and then stall. The lesson is the same.

Workforce reaction will also shape the outcome. Triage tools are sold on the capacity they release. Staff who have lived through repeated industrial disputes and years of operational strain will judge them by whether administrative load falls or whether a new layer of override and audit appears. Clinical trust follows transparent performance data, and ministerial enthusiasm adds little to it. Any deployment that cannot show clinicians how a recommendation was reached will be quietly worked around.

Procurement deserves equal scrutiny. A supplier embedded in triage and scheduling becomes hard to remove, and whoever holds the data holds the stronger bargaining position. Ministers have spoken of treating NHS data as a strategic national asset and of building a domestic life sciences industry. Contracts should therefore settle who owns the data and who may audit the models, and they should do so before go-live. For health-tech firms, the currency in this market is independent evaluation. Companies that publish outcomes by patient group will find the NHS a more receptive customer than those that publish case studies.

Brazil's experiment will take years to read, and the NHS has no need to wait for its verdict before settling its own position. National leaders, the Department of Health and Social Care and the integrated care boards that commission local services should agree who is accountable for an automated ranking and how a patient can challenge it, with equity evidence published before deployment. A queue ordered by software is still a queue ordered by a public body. When a patient waits too long, they will hold that body responsible, and no supplier will be standing next to it.

‍